statistiche ricercatore

statistiche per TERZOLO, Massimo

Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11944
EU - Europa 10432
AS - Asia 5915
SA - Sud America 856
OC - Oceania 242
AF - Africa 187
Continente sconosciuto - Info sul continente non disponibili 26
Totale 29602
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11342
CN - Cina 2959
IT - Italia 2564
DE - Germania 1487
FR - Francia 1021
UA - Ucraina 747
GB - Regno Unito 676
SE - Svezia 669
KR - Corea 595
JP - Giappone 586
FI - Finlandia 487
ES - Italia 459
PL - Polonia 446
BR - Brasile 442
CA - Canada 419
TR - Turchia 373
VN - Vietnam 367
NL - Olanda 352
AT - Austria 256
IN - India 237
AU - Australia 214
GR - Grecia 169
RU - Federazione Russa 169
CH - Svizzera 160
MX - Messico 152
AR - Argentina 145
TW - Taiwan 137
DK - Danimarca 111
RO - Romania 106
CO - Colombia 100
PT - Portogallo 95
BE - Belgio 94
TH - Thailandia 90
HK - Hong Kong 84
IL - Israele 78
CL - Cile 71
RS - Serbia 59
SN - Senegal 56
ID - Indonesia 52
IE - Irlanda 52
PH - Filippine 52
EC - Ecuador 51
MY - Malesia 51
CZ - Repubblica Ceca 46
NO - Norvegia 46
SG - Singapore 45
DZ - Algeria 43
HR - Croazia 35
HU - Ungheria 35
IQ - Iraq 28
NZ - Nuova Zelanda 28
IR - Iran 25
PK - Pakistan 23
SA - Arabia Saudita 23
EU - Europa 21
PE - Perù 20
ZA - Sudafrica 20
AE - Emirati Arabi Uniti 19
EG - Egitto 18
BG - Bulgaria 17
SY - Repubblica araba siriana 16
KE - Kenya 15
SI - Slovenia 15
TN - Tunisia 14
UZ - Uzbekistan 14
VE - Venezuela 13
BY - Bielorussia 12
SK - Slovacchia (Repubblica Slovacca) 11
QA - Qatar 10
MT - Malta 8
MU - Mauritius 8
CY - Cipro 7
JO - Giordania 7
LB - Libano 7
MK - Macedonia 7
OM - Oman 7
PA - Panama 7
UY - Uruguay 7
GT - Guatemala 6
LT - Lituania 6
BO - Bolivia 5
MA - Marocco 5
AP - ???statistics.table.value.countryCode.AP??? 4
BA - Bosnia-Erzegovina 4
JM - Giamaica 4
KW - Kuwait 4
LK - Sri Lanka 4
BD - Bangladesh 3
CU - Cuba 3
GE - Georgia 3
KZ - Kazakistan 3
LU - Lussemburgo 3
LV - Lettonia 3
NG - Nigeria 3
NP - Nepal 3
AM - Armenia 2
CR - Costa Rica 2
EE - Estonia 2
PR - Porto Rico 2
PY - Paraguay 2
Totale 29585
Salva come PNG Salva come JPEG
Città #
Beijing 1791
Fairfield 1148
Houston 1001
Redwood City 891
Woodbridge 607
Ann Arbor 562
Torino 527
Wilmington 524
Seattle 495
Ashburn 493
Cambridge 426
Jacksonville 405
Villeurbanne 333
Warsaw 318
Pisa 267
Dong Ket 226
Dearborn 214
Vienna 209
Shanghai 169
Milan 168
Würzburg 154
Rochester 146
Tokyo 146
Fremont 130
Hangzhou 116
Guangzhou 102
Taipei 102
Toronto 97
San Diego 94
Seoul 93
Paris 91
Rome 84
Nanjing 79
Brescia 77
Buenos Aires 76
São Paulo 72
New York 69
Chengdu 68
Bethesda 65
Madrid 59
Istanbul 58
Santiago 56
Ankara 54
Verona 51
Athens 50
Phoenix 47
London 46
Los Angeles 45
Canberra 44
Seongnam 44
Hefei 43
Moscow 43
Polska 43
Central District 41
Munich 41
Barcelona 40
Düsseldorf 40
Zhengzhou 40
Florence 39
Quito 39
Bologna 38
Leiden 38
Berlin 37
Lachine 37
Mountain View 37
Ottawa 36
Pittsburgh 36
Mexico 35
Rotterdam 33
Silver Spring 33
Montréal 32
New Delhi 32
Singapore 31
Duncan 30
Jinan 30
Boston 29
Padova 29
Birmingham 28
Belgrade 27
Bucharest 27
Philadelphia 27
Chicago 26
Oslo 26
Schwelm 26
Utrecht 26
Baltimore 25
Changsha 25
Chatsworth 25
Columbus 25
Jakarta 25
Québec 25
Tampa 25
Brisbane 23
Changchun 23
Rio De Janeiro 23
Serra 23
Wuhan 23
Zurich 23
Memphis 22
Munro 22
Totale 14741
Salva come PNG Salva come JPEG
Nome #
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. 5043
The Reticulin Algorithm for Adrenocortical Tumor Diagnosis: A Multicentric Validation Study on 245 Unpublished Cases. 672
Practical treatment using mitotane for adrenocortical carcinoma. 635
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. 633
Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. 605
Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma 508
Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior. 480
Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. 467
Hypertension and Acromegaly 386
Long-term follow-up in adrenal incidentalomas: an Italian Multicenter Study. 377
Management of adrenal cancer: a 2013 update. 369
New perspectives for mitotane treatment of adrenocortical carcinoma 369
AME position statement on adrenal incidentaloma. 366
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. 348
Autonomous hypercortisolism: definition and clinical implications 341
Oncocytic Adrenocortical Tumors: Diagnostic Algorithm and Mitochondrial DNA Profile in 27 Cases. 338
Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. 326
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. 313
Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. 308
Comparison of Two Mitotane Starting dose Regimens in Patients with Advanced Adrenocortical Carcinoma. 304
Combination Chemotherapy in Advanced Adrenocortical Carcinoma. 303
Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE) 273
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas 271
Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer 245
Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing's syndrome: A systematic review and meta-Analysis 245
microRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations 241
Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. 236
Management of adjuvant mitotane therapy following resection of adrenal cancer. 235
MITOTANE LEVELS PREDICT THE OUTCOME OF PATIENTS WITH ADRENOCORTICAL CARCINOMA TREATED ADJUVANTLY FOLLOWING RADICAL RESECTION. 233
Screening of Cushing's Syndrome in Outpatients with Type 2 Diabetes: Results of a Prospective Multicentric Study in Italy. 229
Merits and pitfalls of mifepristone in Cushing's syndrome 229
Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas 224
18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma. 216
RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization 201
Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates 188
ENSAT registry-based randomized clinical trials for adrenocortical carcinoma 188
Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma 181
Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. 178
Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma. 175
Analysis of BCLI, N363S and ER22/23EK polymorphisms of the glucocorticoid receptor gene in adrenal incidentalomas 174
Adjuvant mitotane treatment for adrenocortical carcinoma 168
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease 168
Surgical remission of Cushing's syndrome reduces cardiovascular risk. 161
Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma 157
Abiraterone and increased survival in metastatic prostate cancer. 154
Cortisol secretion, bone health, and bone loss: a cross-sectional and prospective study in normal nonosteoporotic women in the early postmenopausal period. 154
Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency. 153
Predictors of morbidity and mortality in acromegaly: an Italian survey. 148
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 145
Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma. 144
Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment. 139
Dual-Energy X-ray Absorptiometry Predictors of Vertebral Deformities in Beta-Thalassemia Major 138
Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma 134
Diagnosi e terapia del carcinoma corticosurrenalico 131
In vitro antitumor activity of progesterone in human adrenocortical carcinoma. 131
Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. 130
Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. 128
Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. 125
Genetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 115
Treatment with 90Y/177Lu DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors 113
Thyroid and colorectal cancer screening in acromegaly patients: Should it be different from that in the general population? 113
Laboratory differentiation of Cushing's syndrome 113
24-hour profiles of blood pressure and heart rate in Cushing's syndrome. Evidence for differential control of cardiovascular variables by glucocorticoids. 110
Acromegaly is associated with increased cancer risk: a survey in Italy 110
Novel mutation of PPOX gene in a patient with abdominal pain and syndrome of inappropriate antidiuresis. 109
Long term safety of recombinant human growth hormone (rhGH) in patients treated during childhood 108
Analysis of BclI, N363S and ER22/23EK polymorphism of the glucocorticoid receptor gene in a large series of patients with adrenal incidentaloma 103
Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study 102
Evaluation of midnight salivary cortisol as a predictor factor for common carotid arteries intima media thickness in patients with clinically inapparent adrenal adenomas 101
CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma 99
[Subclinical Cushing's syndrome in adrenal incidentalomas] 99
Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. 97
Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: A multicenter study 96
18-Hydroxycorticosterone, 18-Hydroxycortisol, and 18-Oxocortisol in the Diagnosis of Primary Aldosteronism and Its Subtypes 95
Determination of salivary cortisol to assess time related changes of the adrenal response to stress in critically ill patients 94
Adrenal incidentaloma, a five year experience. 93
Acute administration of melatonin at two opposite circadian stages does not change responses to gonadotropin releasing hormone, thyrotropin releasing hormone and ACTH in healthy adult males. 93
Insights on the natural history of adrenal incidentalomas 90
Biochemical stress evaluation after medial parapatellar and subvastus approach in total knee replacement. 88
Adrenal incidentalomas and subclinical Cushing's syndrome: is there evidence for glucocorticoid-induced osteoporosis? 86
Effects of high-intensity isokinetic exercise on salivary cortisol in athletes with different training schedules: relationships to serum cortisol and lactate 86
Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. 85
Cyclic Cushing's syndrome due to ectopic ACTH secretion by an adrenal pheochromocytoma. 83
[Drugs and andrological side-effects] 82
Intermittent everolimus administration for malignant insulinoma 80
A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients 80
Sindrome di Cushing: l’esperienza dell’Ospedale San Luigi di Orbassano 80
May an adrenal incidentaloma change its nature? 79
Adjunctive treatment of adrenocortical carcinoma 78
Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. 77
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells 77
Valutazione prospettica di pazienti operati radicalmente per carcinoma corticosurrenalico in trattamento con mitotane adiuvante: correlazioni tra indici di massa corporea, livelli di mitotanemia ed efficacia. 76
Subclinical Cushing's syndrome 75
Similarity of the nocturnal profile of serum melatonin at early puberty and early adulthood. 73
Melatonin and human cancer. 73
Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment 73
Circadian profile of serum melatonin in Cushing's disease and acromegaly. 72
Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome. 71
Desmopressin test in mild Cushing syndrome. 71
Evaluation of cardiovascular risk factors in patients with incidentally discovered adrenal adenoma during a follow-up longer than five years 70
Totale 24029
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31021
article - articoli 0
book - libri 0
conference - conferenze 1813
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32834
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2016/2017806 0000 00 00 00649157
2017/20184638 209332272176 246158 211617 1446601183187
2018/20193931 217151244187 218280 207437 235428821506
2019/20207012 485402511675 520838 715652 760573467414
2020/20216890 520435579427 592512 635551 580689551819
2021/20226448 477516525690 598439 613605 4565509790
Totale 31021
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie-Privacy
Logo CINECA  Copyright © 2022